CN104961687B - 1,2‑二嗪衍生物及其制剂、用途 - Google Patents
1,2‑二嗪衍生物及其制剂、用途 Download PDFInfo
- Publication number
- CN104961687B CN104961687B CN201510296159.7A CN201510296159A CN104961687B CN 104961687 B CN104961687 B CN 104961687B CN 201510296159 A CN201510296159 A CN 201510296159A CN 104961687 B CN104961687 B CN 104961687B
- Authority
- CN
- China
- Prior art keywords
- preparation
- medicine
- diazine
- calcium
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510296159.7A CN104961687B (zh) | 2015-06-03 | 2015-06-03 | 1,2‑二嗪衍生物及其制剂、用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510296159.7A CN104961687B (zh) | 2015-06-03 | 2015-06-03 | 1,2‑二嗪衍生物及其制剂、用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104961687A CN104961687A (zh) | 2015-10-07 |
CN104961687B true CN104961687B (zh) | 2017-07-25 |
Family
ID=54215812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510296159.7A Active CN104961687B (zh) | 2015-06-03 | 2015-06-03 | 1,2‑二嗪衍生物及其制剂、用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104961687B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503852A (en) * | 1992-03-11 | 1996-04-02 | Pharmaceutical Discovery Corporation | Method for making self-assembling diketopiperazine drug delivery system |
CN1190893A (zh) * | 1995-03-31 | 1998-08-19 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
WO2002045754A2 (en) * | 2000-12-06 | 2002-06-13 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
CN1596248A (zh) * | 2001-11-13 | 2005-03-16 | 艾米斯菲尔技术有限公司 | 用于递送活性剂的苯氧基胺化合物和组合物 |
CN1671418A (zh) * | 2002-08-01 | 2005-09-21 | 诺瓦提斯公司 | 降钙素的口服施用 |
CN101557827A (zh) * | 2006-08-31 | 2009-10-14 | 诺瓦提斯公司 | 用于口服递送的包含hgh的药物组合物 |
CN101621991A (zh) * | 2007-03-02 | 2010-01-06 | 诺瓦提斯公司 | 降钙素的口服施用 |
WO2010111271A1 (en) * | 2009-03-27 | 2010-09-30 | Sdg, Inc. (An Ohio Corporation) | Orally bioavailable lipid-based constructs |
US20120189666A1 (en) * | 2004-08-13 | 2012-07-26 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
CN103458873A (zh) * | 2011-04-14 | 2013-12-18 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
-
2015
- 2015-06-03 CN CN201510296159.7A patent/CN104961687B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5503852A (en) * | 1992-03-11 | 1996-04-02 | Pharmaceutical Discovery Corporation | Method for making self-assembling diketopiperazine drug delivery system |
CN1190893A (zh) * | 1995-03-31 | 1998-08-19 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
WO2002045754A2 (en) * | 2000-12-06 | 2002-06-13 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
CN1596248A (zh) * | 2001-11-13 | 2005-03-16 | 艾米斯菲尔技术有限公司 | 用于递送活性剂的苯氧基胺化合物和组合物 |
CN1671418A (zh) * | 2002-08-01 | 2005-09-21 | 诺瓦提斯公司 | 降钙素的口服施用 |
US20120189666A1 (en) * | 2004-08-13 | 2012-07-26 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
CN101557827A (zh) * | 2006-08-31 | 2009-10-14 | 诺瓦提斯公司 | 用于口服递送的包含hgh的药物组合物 |
CN101621991A (zh) * | 2007-03-02 | 2010-01-06 | 诺瓦提斯公司 | 降钙素的口服施用 |
WO2010111271A1 (en) * | 2009-03-27 | 2010-09-30 | Sdg, Inc. (An Ohio Corporation) | Orally bioavailable lipid-based constructs |
CN103458873A (zh) * | 2011-04-14 | 2013-12-18 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
Non-Patent Citations (3)
Title |
---|
RN:1699385-52-8;ACS,STN Registry数据库;《ACS,STN Registry数据库》;20150506 * |
多肽和蛋白类药物口服给药的可行性探讨;黄健,等;《国际药学研究杂志》;20070831;第34卷(第4期);第298-300页 * |
降钙素口服制剂的研究进展;刘琦,等;《中国药房》;20141231;第25卷(第29期);第2777-2780页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104961687A (zh) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7820676B2 (en) | Diketopiperazine salts for drug delivery and related methods | |
KR102223224B1 (ko) | 이중으로 유도화된 키토산 나노입자 및 이의 제조 방법과 생체 내 유전자 도입을 위하여 이를 이용하는 방법 | |
JPH02500669A (ja) | 薬物送達システム | |
JP5970189B2 (ja) | 医薬調製物 | |
CN103781489A (zh) | 用于基于血红蛋白的氧载体的口服递送 | |
CN105056212A (zh) | 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法 | |
CN104055735B (zh) | 一种萨摩鲁泰的脂质体及其制备方法 | |
CN113876716B (zh) | 一种治疗胃肠道疾病的生物粘附性纳米粒及其制备方法 | |
CN107432936A (zh) | 一种改性壳聚糖的用途和包含该改性壳聚糖的纳米复合物 | |
CN102481287B (zh) | 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法 | |
CN104961687B (zh) | 1,2‑二嗪衍生物及其制剂、用途 | |
CN104739806A (zh) | 口服胰岛素复合微囊及制备方法 | |
CN109568601B (zh) | 一种蛋白多肽类药物双重微球及其制备方法和胰岛素双重微球 | |
CN109498571B (zh) | 一种艾司奥美拉唑钠缓释微球及其制备方法 | |
CN104546722B (zh) | 米铂脂质体和制法 | |
CN110063946A (zh) | 一种包载阿帕替尼的壳聚糖海藻酸钠微球制备方法及应用 | |
CN101555212B (zh) | 能输送生物活性物质的合成小分子化合物及其应用 | |
CN101959532B (zh) | 经鼻给药用药物组合物 | |
CN109675020B (zh) | 一种口服glp-1多肽类纳米制剂及其制备方法和应用 | |
WO2004054602A1 (ja) | 経口投与可能なタンパク質製剤およびその経口投与法 | |
CN102670611B (zh) | 抗结核药物三联复方微球血管靶向栓塞缓释剂及其制备方法和用途 | |
CN107412166B (zh) | 一种纳米复合吸附磷材料及其制备与应用 | |
CN114732789B (zh) | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 | |
EP4316471A1 (en) | Oral nanoparticles for bioactive compound, and method of preparing same | |
EP2150243A2 (en) | Compositions and methods for enhancing active agent absorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200107 Address after: Room 108, floor 1, building 3, Shiyuan West Road North, Nanxun Avenue West, Nanxun Economic Development Zone, Huzhou City, Zhejiang Province Patentee after: Zhejiang Weitai Biotechnology Co.,Ltd. Address before: Wuzhong District town Suzhou city Jiangsu province 215000 gold Jinchang Road No. 360 Patentee before: SUZHOU VIVOTIDE BIOTECHNOLOGIES Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: 1,2-dizine derivatives and their preparations, uses Effective date of registration: 20230705 Granted publication date: 20170725 Pledgee: Nanxun rural commercial bank Limited by Share Ltd. Zhejiang Pledgor: Zhejiang Weitai Biotechnology Co.,Ltd. Registration number: Y2023980047503 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |